{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:15:25Z","timestamp":1759342525166,"version":"3.44.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.humpath.2022.06.014","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T11:34:59Z","timestamp":1655206499000},"page":"135-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Drug-induced digestive tract injury: decoding some invisible offenders"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-2859","authenticated-orcid":false,"given":"Dipti M.","family":"Karamchandani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2022.06.014_bib1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.5858\/arpa.2020-0535-RA","article-title":"New kids on the block","volume":"145","author":"Karamchandani","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.06.014_bib2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/PAS.0b013e31828f5b3a","article-title":"Doxycycline-induced gastric and esophageal mucosal injuries with vascular degeneration","volume":"37","author":"Xiao","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.humpath.2017.02.011","article-title":"Doxycycline-induced gastrointestinal injury","volume":"66","author":"Affolter","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/PAS.0000000000000792","article-title":"Vascular injury characterizes doxycycline-induced upper gastrointestinal tract mucosal injury","volume":"41","author":"Shih","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib5","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1097\/PAS.0b013e31828f5a3f","article-title":"Vascular wall degeneration in doxycycline-related esophagitis","volume":"37","author":"Medlicott","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1757-1626-1-144","article-title":"Doxycycline-induced ulceration mimicking esophageal cancer","volume":"1","author":"Tahan","year":"2008","journal-title":"Cases J"},{"key":"10.1016\/j.humpath.2022.06.014_bib7","first-page":"232","article-title":"A case report of doxycycline induced esophageal and gastric ulcer","volume":"13","author":"Akbayir","year":"2002","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.humpath.2022.06.014_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1442-2050.2004.00384.x","article-title":"Doxycycline-induced pill esophagitis","volume":"17","author":"Kadayifci","year":"2004","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.humpath.2022.06.014_bib9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1161\/01.STR.0000129334.05181.b6","article-title":"Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model","volume":"35","author":"Lee","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.humpath.2022.06.014_bib10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/sj.jcbfm.9600268","article-title":"Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation","volume":"26","author":"Lee","year":"2006","journal-title":"J Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.humpath.2022.06.014_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/01.mcg.0000129058.69524.90","article-title":"Mid-esophageal ulceration and candidiasis-associated distal esophagitis as two distinct clinical patterns of tetracycline or doxycycline-induced esophageal injury","volume":"38","author":"Gencosmanoglu","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.humpath.2022.06.014_bib12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/BF01540274","article-title":"Endoscopic biopsy is diagnostic in gastric antral vascular ectasia. The \"watermelon stomach\"","volume":"34","author":"Gilliam","year":"1989","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.humpath.2022.06.014_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1055\/s-2004-814112","article-title":"Endoscopic treatment outcomes in watermelon stomach patients with and without portal hypertension","volume":"36","author":"Dulai","year":"2004","journal-title":"Endoscopy"},{"key":"10.1016\/j.humpath.2022.06.014_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4254\/wjh.v8.i4.231","article-title":"Portal hypertensive gastropathy: a systematic review of the pathophysiology, clinical presentation, natural history and therapy","volume":"8","author":"Gjeorgjievski","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.humpath.2022.06.014_bib15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","article-title":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group","volume":"64","author":"Mayer","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.humpath.2022.06.014_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(94)91766-3","article-title":"Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.humpath.2022.06.014_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International liver transplantation society consensus statement on immunosuppression in liver transplant recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.humpath.2022.06.014_bib18","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.humpath.2022.06.014_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/PAS.0000000000001761","article-title":"Histologic features of tacrolimus-induced colonic injury","volume":"46","author":"Hissong","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1432-2277.2009.01009.x","article-title":"Two cases of severe de novo colitis in kidney transplant recipients after conversion to prolonged-release tacrolimus","volume":"23","author":"Kurnatowska","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.humpath.2022.06.014_bib21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1399-3046.2006.00538.x","article-title":"Tacrolimus-associated eosinophilic gastroenterocolitis in pediatric liver transplant recipients: role of potential food allergies in pathogenesis","volume":"10","author":"Saeed","year":"2006","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.humpath.2022.06.014_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/PAS.0b013e31829ab1ef","article-title":"Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis","volume":"37","author":"Star","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s001050050013","article-title":"[Mycophenolate mofetil: a new immunosuppressive drug in dermatology and its possible uses]","volume":"51","author":"Geilen","year":"2000","journal-title":"Hautarzt"},{"key":"10.1016\/j.humpath.2022.06.014_bib24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jclinpath-2018-205388","article-title":"Apoptotic colopathy: a pragmatic approach to diagnosis","volume":"71","author":"Karamchandani","year":"2018","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0300-2977(00)00069-3","article-title":"Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine","volume":"57","author":"Smak Gregoor","year":"2000","journal-title":"Neth J Med"},{"key":"10.1016\/j.humpath.2022.06.014_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/bmt.2011.104","article-title":"Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation","volume":"47","author":"Johnston","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.humpath.2022.06.014_bib27","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/j.1875-9114.1997.tb03082.x","article-title":"Mycophenolate mofetil","volume":"17","author":"Sievers","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.humpath.2022.06.014_bib28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/PAS.0b013e3181a755bd","article-title":"Mycophenolic acid (cellcept and myofortic) induced injury of the upper GI tract","volume":"33","author":"Nguyen","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/modpathol.2009.44","article-title":"Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil","volume":"22","author":"Selbst","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1365-2559.2012.04305.x","article-title":"Microscopic features associated with mycophenolate mofetil in gastric and colonic biopsies","volume":"61","author":"Coyne","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2022.06.014_bib31","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e31816bf3fe","article-title":"Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes","volume":"32","author":"Parfitt","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00007890-199810270-00027","article-title":"Mycophenolate mofetil-induced villous atrophy","volume":"66","author":"Ducloux","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.humpath.2022.06.014_bib33","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0041-1345(01)01951-0","article-title":"Graft-versus-host disease-like features in mycophenolate mofetil-related colitis","volume":"33","author":"Papadimitriou","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.humpath.2022.06.014_bib34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/106689690301100406","article-title":"Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern","volume":"11","author":"Papadimitriou","year":"2003","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/jclinpath-2012-200888","article-title":"Pointers and pitfalls of mycophenolate-associated colitis","volume":"66","author":"Lee","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib36","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00018-008-7511-x","article-title":"NSAIDs and apoptosis","volume":"65","author":"Jana","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.humpath.2022.06.014_bib37","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1097\/PAS.0b013e3180cab60c","article-title":"Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review","volume":"31","author":"Daniels","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00007890-198506000-00019","article-title":"Mucosal damage simulating acute graft-versus-host reaction in cytomegalovirus colitis","volume":"39","author":"Snover","year":"1985","journal-title":"Transplantation"},{"key":"10.1016\/j.humpath.2022.06.014_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/PAP.0000000000000346","article-title":"Gastrointestinal and hepatobiliary immune-related adverse events: a histopathologic review","author":"Alruwaii","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-017-2267-z","article-title":"Immune checkpoint inhibitor colitis: the flip side of the wonder drugs","volume":"472","author":"Assarzadegan","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2022.06.014_bib41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/jclinpath-2018-205143","article-title":"Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective","volume":"71","author":"Karamchandani","year":"2018","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib42","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2022.06.014_bib43","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2022.06.014_bib44","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAS.0000000000001730","article-title":"Histopathology of gastrointestinal immune-related adverse events: a practical review for the practicing pathologist","volume":"46","author":"Zhang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib45","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.humpath.2022.06.014_bib46","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: a systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.humpath.2022.06.014_bib47","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.humpath.2022.06.014_bib48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fimmu.2017.01547","article-title":"Checkpoint blockade toxicity and immune homeostasis\u00a0in the gastrointestinal tract","volume":"8","author":"Dougan","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.humpath.2022.06.014_bib49","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2022.06.014_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004560","article-title":"Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis","volume":"10","author":"Ma","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.humpath.2022.06.014_bib51","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/his.13118","article-title":"PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'","volume":"70","author":"Gonzalez","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2022.06.014_bib52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/PAS.0000000000000829","article-title":"Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies","volume":"41","author":"Chen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/his.13963","article-title":"Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies","volume":"76","author":"Zhang","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2022.06.014_bib54","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/joim.12744","article-title":"Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis","volume":"283","author":"Adler","year":"2018","journal-title":"J Intern Med"},{"key":"10.1016\/j.humpath.2022.06.014_bib55","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cgh.2015.12.028","article-title":"Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis","volume":"14","author":"Verschuren","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.humpath.2022.06.014_bib56","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.humpath.2022.06.014_bib57","article-title":"Immune checkpoint inhibitor-induced colitis presenting as lymphocytic colitis","volume":"13","author":"Khan","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.humpath.2022.06.014_bib58","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/CMR.0000000000000665","article-title":"Anti-PD-1 induced collagenous colitis in metastatic melanoma: a rare severe adverse event","volume":"30","author":"Janela-Lapert","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.humpath.2022.06.014_bib59","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CMR.0000000000000252","article-title":"Anti-PD1-induced collagenous colitis in a melanoma patient","volume":"26","author":"Baroudjian","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.humpath.2022.06.014_bib60","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/his.14248","article-title":"Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis","volume":"78","author":"Isidro","year":"2021","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2022.06.014_bib61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ibd\/izy240","article-title":"Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity?","volume":"25","author":"Choi","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.humpath.2022.06.014_bib62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.humpath.2022.06.014_bib63","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.humpath.2022.06.014_bib64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/his.14029","article-title":"Morphological spectrum of immune check-point inhibitor therapy-associated gastritis","volume":"76","author":"Johncilla","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2022.06.014_bib65","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/CMR.0000000000000502","article-title":"Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma","volume":"28","author":"Yip","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.humpath.2022.06.014_bib66","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5858\/arpa.2019-0700-OA","article-title":"Immune checkpoint inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, Helicobacter pylori gastritis and celiac disease","volume":"145","author":"Irshaid","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.06.014_bib67","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/annonc\/mdx403","article-title":"Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies","volume":"28","author":"Collins","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2022.06.014_bib68","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-018-0332-z","article-title":"Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab","volume":"6","author":"Acero Brand","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.humpath.2022.06.014_bib69","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2020.7675","article-title":"Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis","volume":"19","author":"Panneerselvam","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.humpath.2022.06.014_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.334","article-title":"Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient","volume":"6","author":"Onuki","year":"2018","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.humpath.2022.06.014_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012644","article-title":"Angiotensin III\/AT2 receptor\/NHE3 signaling pathway in the proximal tubules of the kidney: a novel natriuretic and antihypertensive mechanism in hypertension","volume":"8","author":"Zhuo","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.humpath.2022.06.014_bib72","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.mayocp.2012.06.003","article-title":"Severe spruelike enteropathy associated with olmesartan","volume":"87","author":"Rubio-Tapia","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.humpath.2022.06.014_bib73","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.5858\/arpa.2015-0204-RA","article-title":"Olmesartan-associated enteropathy: a review of clinical and histologic findings","volume":"139","author":"Choi","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.06.014_bib74","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12876-021-01926-y","article-title":"Severe spruelike enteropathy and collagenous colitis caused by olmesartan","volume":"21","author":"Kaneko","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.humpath.2022.06.014_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.humpath.2015.12.001","article-title":"Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology","volume":"50","author":"Burbure","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2022.06.014_bib76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.12780","article-title":"Systematic review: sprue-like enteropathy associated with olmesartan","volume":"40","author":"Ianiro","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.humpath.2022.06.014_bib77","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/apt.12937","article-title":"Olmesartan-associated enteropathy: results of a national survey","volume":"40","author":"Marthey","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.humpath.2022.06.014_bib78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.dld.2013.12.014","article-title":"Five cases of sprue-like enteropathy in patients treated by olmesartan","volume":"46","author":"Theophile","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.humpath.2022.06.014_bib79","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/PAT.0000000000000104","article-title":"Olmesartan induced enterocolitis","volume":"46","author":"Gallivan","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.humpath.2022.06.014_bib80","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.3748\/wjg.v19.i40.6928","article-title":"Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug","volume":"19","author":"Nielsen","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.humpath.2022.06.014_bib81","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MCG.0b013e31829a27e6","article-title":"Olmesartan-associated sprue-like\u00a0enteropathy","volume":"47","author":"Stanich","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.humpath.2022.06.014_bib82","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4321\/S1130-01082014000200011","article-title":"Severe spruelike enteropathy due to olmesartan","volume":"106","author":"Fiorucci","year":"2014","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.humpath.2022.06.014_bib83","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/apt.12850","article-title":"Letter: telmisartan-associated enteropathy - is there any class effect?","volume":"40","author":"Cyrany","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.humpath.2022.06.014_bib84","first-page":"87","article-title":"Celiac disease-like enteropathy due to antihypertensive therapy with the angiotensin-II receptor type 1 inhibitor eprosartan","volume":"51","author":"Maier","year":"2015","journal-title":"Cesk Patol"},{"key":"10.1016\/j.humpath.2022.06.014_bib85","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.mayocp.2012.10.005","article-title":"Olmesartan and intestinal adverse effects in the ROADMAP study","volume":"87","author":"Menne","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.humpath.2022.06.014_bib86","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.mayocp.2014.05.012","article-title":"Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study","volume":"89","author":"Greywoode","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.humpath.2022.06.014_bib87","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cgh.2007.05.013","article-title":"Adult autoimmune enteropathy: mayo clinic rochester experience","volume":"5","author":"Akram","year":"2007","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817722001599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817722001599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:41:31Z","timestamp":1758645691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817722001599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":87,"alternative-id":["S0046817722001599"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2022.06.014","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced digestive tract injury: decoding some invisible offenders","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2022.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}